Redeye positively views the FDA approval of extended labelling for Nevisense, allowing measurements ...
CapMan just announced its second exit from its Infra I fund (2020).
Nokian Panimo delivered a solid H2 in line with expectations, entering 2026 with a record product la...
Xplora reported record results in the Q4 report, and it reported gross profit of NOK 312m, 7% higher...
mResell levererade 131 % intäktstillväxt i Q4’25 trots en temporär regulatorisk påverkan.
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust i det fjärde kva...
Hanza redovisade ett starkt bokslut för 2025 med rekordhög marginal.
Redeye returns with an update following Guldbrev's mixed Q4 report that posted stronger growth than ...
Redeye comments on MindArk’s Q4 results, which came in somewhat softer than expected.
Redeye provides its initial take on Heliospectra’s Q4 results, which showed softer-than-expected fig...
Redeye provides an initial take following Paxman’s Q4 2025 report.
Physitracks Q4 results aligned with its preliminary figures, highlighted by continued margin expansi...
Redeye views Xplora's Q4 2025 results positively despite a miss against its own forecasts, as the pr...
With key trials successfully initiated and the balance sheet strengthened in 2025, Curasight is set ...
* Q4 sales and EBITDA 7% and EBITDA 23% above driven by Senior * Strong growth in senior device reve...
IDL saw a comeback in TUBEX in Q3, and total sales came in SEK1m above our forecast, with OPEX relat...
Xplora's gross profit came in stronger than expected at NOK 312m, 7% higher than consensus, driven b...
Redeye comments on Sivers’ Q4 report, which showed solid FX-neutral growth and strong Photonics hard...
Tallinna Sadam's revenue growth was 1% y/y and close to consensus (LSEG Data & Analytics) expectatio...
Incap's Q4 net sales missed market consensus (LSEG Data & Analytics), but profitability was better t...
